Evidence map›Paper›PMID 34521186›Full record

ArticleThe Korean journal of internal medicine2022

Alleviation of renal ischemia/reperfusion injury by exosomes from induced pluripotent stem cell-derived mesenchymal stem cells.

Sun Woo Lim, Kyung Woon Kim, Bo Mi Kim, Yoo Jin Shin, Kang Luo, Yi Quan, Sheng Cui, Eun Jeong Ko, Byung Ha Chung, Chul Woo Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Clinical applications of stem cell-derived exosomes.Signal transduction and targeted therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sun Woo LimTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kyung Woon KimConvergent Research Consortium for Immunologic disease, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Bo Mi KimConvergent Research Consortium for Immunologic disease, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yoo Jin ShinTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kang LuoTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yi QuanTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sheng CuiTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Eun Jeong KoTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Byung Ha ChungTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chul Woo YangTransplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Funding

Ministry of Health and Welfare HI14C3417Ministry of Science, ICT and Future PlanningNational Research Foundation of Korea 2018R1D1A1A02043014
6 · The paper itself

Abstract

BACKGROUND/

aimsRenal ischemia followed by reperfusion (I/R) is a leading cause of acute kidney injury (AKI), which is closely associated with high morbidity and mortality. Studies have shown that induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs) exert powerful therapeutic effects in renal ischemia. However, the efficacy of iMSC-derived exosomes (iExo) on I/R injuries remains largely unknown.

methodsHuman iPSCs were differentiated into iMSCs using a modified one-step method. Ultrafiltration, combined with purification, was used to isolate iExo from iMSCs. iExo was administered following I/R injury in a mouse model. The effect of iExo on I/R injury was assessed through changes in renal function, histology, and expression of oxidative stress, inflammation, and apoptosis markers. Further, we evaluated its association with the extracellular signal-regulated kinase (ERK) 1/2 signaling pathway.

resultsMice subjected to I/R injury exhibited typical AKI patterns; serum creatinine level, tubular necrosis, apoptosis, inflammatory cytokine production, and oxidative stress were markedly increased compared to sham mice. However, treatment with iExo attenuated these changes, significantly improving renal function and tissue damage, similar to the renoprotective effects of iMSCs on I/R injury. Significant induction of activated ERK 1/2 signaling molecules was observed in mice treated with iExo compared to those in the I/R injury group.

conclusionThe present study demonstrates that iExo administration ameliorated renal damage following I/R, suggesting that iMSC-derived exosomes may provide a novel therapeutic approach for AKI treatment.

Indexed as

Acute Kidney InjuryExosomesInduced Pluripotent Stem CellsMesenchymal Stem CellsReperfusion InjuryAnimalsApoptosisFemaleHumansIschemiaKidneyMaleMiceAcute kidney injuryExosomesInduced pluripotent stem cellMesenchymal stem cellReperfusion injury

Identifiers

PMID34521186
PMCPMC8925954

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.